| First Author | Rosenbaum SR | Year | 2020 |
| Journal | Cell Rep | Volume | 30 |
| Issue | 2 | Pages | 510-524.e6 |
| PubMed ID | 31940493 | Mgi Jnum | J:287418 |
| Mgi Id | MGI:6415774 | Doi | 10.1016/j.celrep.2019.12.036 |
| Citation | Rosenbaum SR, et al. (2020) FOXD3 Regulates VISTA Expression in Melanoma. Cell Rep 30(2):510-524.e6 |
| abstractText | Immune checkpoint inhibitors have improved patient survival in melanoma, but the innate resistance of many patients necessitates the investigation of alternative immune targets. Many immune checkpoint proteins lack proper characterization, including V-domain Ig suppressor of T cell activation (VISTA). VISTA expression on immune cells can suppress T cell activity; however, few studies have investigated its expression and regulation in cancer cells. In this study, we observe that VISTA is expressed in melanoma patient samples and cell lines. Tumor cell-specific expression of VISTA promotes tumor onset in vivo, associated with increased intratumoral T regulatory cells, and enhanced PDL-1 expression on tumor-infiltrating macrophages. VISTA transcript levels are regulated by the stemness factor Forkhead box D3 (FOXD3). BRAF inhibition upregulates FOXD3 and reduces VISTA expression. Overall, this study demonstrates melanoma cell expression of VISTA and its regulation by FOXD3, contributing to the rationale for therapeutic strategies that combine targeted inhibitors with immune checkpoint blockade. |
